(Q44251536)

English

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 December 2017

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial (English)

1 reference

Europe PubMed Central

1 December 2017

type 2 diabetes

0 references

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Christopher S. Kovacs

1

1 reference

Europe PubMed Central

1 December 2017

author name string

V Seshiah

2

1 reference

Europe PubMed Central

1 December 2017

R Swallow

3

1 reference

Europe PubMed Central

1 December 2017

R Jones

4

1 reference

Europe PubMed Central

1 December 2017

H Rattunde

5

1 reference

Europe PubMed Central

1 December 2017

H J Woerle

6

1 reference

Europe PubMed Central

1 December 2017

U C Broedl

7

1 reference

Europe PubMed Central

1 December 2017

EMPA-REG PIO™ trial investigators

8

1 reference

Europe PubMed Central

1 December 2017

publication date

22 August 2013

1 reference

Europe PubMed Central

1 December 2017

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

1 December 2017

16

1 reference

Europe PubMed Central

1 December 2017

2

1 reference

Europe PubMed Central

1 December 2017

147-158

1 reference

Europe PubMed Central

1 December 2017

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Intentional weight loss and mortality among overweight individuals with diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Pioglitazone: beyond glucose control.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study.

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Increased mortality of patients with diabetes reporting severe hypoglycemia

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Risk of urinary tract infection and asymptomatic bacteriuria among diabetic and nondiabetic postmenopausal women

1 reference

https://api.crossref.org/works/10.1111%2FDOM.12188

21 January 2018

Identifiers

10.1111/DOM.12188

1 reference

Europe PubMed Central

1 December 2017

1 reference

Europe PubMed Central

1 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44251536&oldid=2108915804"